CClinicalTrials.gg
Enrolling by invitationNCT05941559Updated Nov 29, 2024

EMDR for Persistent Pain in RA

An interventional study of EMDR in Rheumatoid Arthritis, sponsored by Medisch Spectrum Twente. Enrolling by invitation at 1 site in Netherlands. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2024-11-29.

Sponsored by Medisch Spectrum Twente · Not applicable, Interventional, and Treatment

From the registry’s dates

  • Primary completion was expected by Jul 2025, 1 year 3 months ago, but the record still lists the study as enrolling by invitation.
Phase
Not applicable
Study type
Interventional
Enrollment
10
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Study summary

Rationale: Around 20% of rheumatoid arthritis (RA) patients have persistent pain, despite having well-controlled disease activity. There is a significant overlap in underlying mechanisms between post-traumatic stress disorder (PTSD) and persistent pain. Eye Movement Desensitization and Reprocessing (EMDR) is a proven effective treatment for PTSD and evidence is growing that it may also be effective for persistent pain. Objective: To assess the feasibility and estimate the effectiveness of EMDR in RA patients with persistent pain despite inflammation being under control.

Study design: A multiple-baseline single-case experimental design (SCED) across three time series. Participants will be randomized to one of the three time series. Within the time series the start of the intervention is randomly determined. Four participants will be assigned to the shortest, three to the medium and three to the longest baseline length. The SCED study consists of a baseline phase (A1), intervention phase (B), post-treatment phase (A2), follow-up phase 1 (A3), and follow-up phase 2 (A4).

Study population: Subjects are RA patients > 18 years with low disease activity (DAS28\<3.2) at >2 measurements over the previous 12 months and concurrent elevated pain scores (NRS-pain>6).

Intervention (if applicable): EMDR therapy consists of an intake and eight sessions of 90 minutes in total, performed according to the EMDR standard protocol, conducted by four psychologists, all are level-II trained, under the supervision of an EMDR Europe consultant. EMDR focuses on processing traumatic memories, pain-related memories, and current physical pain.

Main study parameters/endpoints: Primary endpoint for effectiveness is the pre-treatment phase A1 to post-treatment phase A2 difference in NRS pain intensity. Feasibility is examined by monitoring recruitment, dropout rates, and treatment satisfaction. Nature and extent of the burden and risks associated with participation, benefit and group relatedness: If the therapy is effective, pain intensity decreases, additional physical complaints of RA decrease and participants experience less discomfort from their pain in daily life. EMDR therapy is an evidence-based treatment for PTSD and the reduction of posttraumatic stress favors the recovery of physical complaints. Participating in the study includes two conversations for inclusion (two times 60 minutes consisting of one telephone conversation and one face-to-face conversation), attending the EMDR therapy intake (one time 90 minutes) and sessions (eight times 90 minutes), and daily registration of complaints (about two minutes per day) via a smartphone application, completing the questionnaires (about 14-28 minutes at six specific time points during the study), and an exit conversation at six months follow up. Daily registration will take 18 to 20 weeks maximum. At the three- and six-month follow-up, participants will be asked to register daily for 14 days. EMDR sessions can be emotionally intense, but never are as challenging as living with unprocessed (traumatic) pain-related memories. There are no risks associated with EMDR therapy.

02

Conditions studied

  • Rheumatoid Arthritis

Keywords

  • Chronic pain
  • EMDR
03

In context

Arthritis

3,554 studies on the registry are indexed under Arthritis; 317 are open to participants now.

This study's planned enrollment of 10 is below the median of 90 across 2,377 interventional studies indexed under Arthritis.

Browse Arthritis studies →

Lead sponsor

Medisch Spectrum Twente is the lead sponsor of 23 studies on the registry; 11 are open to participants now.

Counted across the registry records on this site, refreshed daily.

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Inclusion criteria

  • Clinical diagnosis of RA
  • Stable low disease activity Score in 28 joints, i.e. DAS28 \<3.2 at >2 measurements over the previous 12 months and at the time of inclusion
  • Elevated pain scores (NRS pain >6) at >2 measurements over the previous 12 months and at the time of inclusion
  • Sufficient knowledge of the Dutch language

Exclusion criteria

Exclusion Criteria:

  • An acute condition of psychosis or bipolar disorder
  • An acute suicidal risk
  • Substance dependency
  • Not stable on the use of medication
  • Visual or hearing problems interfering with the EMDR procedure
  • Other psychological/psychiatric treatment
05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
10 participants (estimated)

Study arms

  • Other
    Shortest baseline length

    Intervention starting points are at day 15, 16, 17, 18 or 19.

    Other: EMDR

  • Other
    Medium baseline length

    Intervention starting points are at day 20, 21, 22, 23, and 24.

    Other: EMDR

  • Other
    Longest baseline length

    Intervention starting points are at day 25, 26, 27, 28, or 29.

    Other: EMDR

Interventions

  • OtherEMDR

    Eye Movement Desensitization and Reprocessing

06

What researchers measure

Primary outcomes

  1. Effectiveness

    Difference in Numeric Rating Scale (NRS) pain intensity. Scale 0-6, 0 means never (good outcome), 6 means always (bad outcome)

    Time frame: 100 Days

07

Study locations

1 site
  • Medisch Spectrum Twente
    Enschede, Overijssel 7512KZ, Netherlands
08

References and documents

Individual participant data

Plan to share: Undecided

No publications or documents are linked to this record.

09

Updates

Tracking since Sep 25, 2026
No changes since tracking began. The registry record was last updated on Nov 29, 2024, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT05941559
Lead sponsor
Medisch Spectrum Twente
Collaborators
University of Twente, Leiden University Medical Center
Responsible party
Harald E. Vonkeman (prof.dr., Medisch Spectrum Twente) — Principal investigator
First posted
Jul 12, 2023
Start date
Aug 22, 2024
Primary completion
Jul 1, 2025 (estimated)
Completion
Dec 1, 2025 (estimated)
Last update
Nov 29, 2024

Oversight

Data monitoring committee
No
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

No contact was published for this record. The registry link below has the sponsor’s details.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion